Your browser doesn't support javascript.
loading
Influencing factors to excellent response in differentiated thyroid cancer after 131I therapy and ongoing assessment / 中国肿瘤临床
Chinese Journal of Clinical Oncology ; (24): 18-21, 2018.
Artigo em Chinês | WPRIM | ID: wpr-706748
ABSTRACT

Objective:

To continuously evaluate the response of differentiated thyroid cancer(DTC)after radioiodine therapy,and to an-alyze influencing factors for excellent response.

Methods:

Data of 237 patients with non-distant metastatic DTC treated in Peking Union Medical College Hospital were retrospectively analyzed,and the changes in response were evaluated(excellent response,ER;biochemical incomplete response,BIR;and structure incomplete response,SIR)2 years after receiving the 131I therapy.The responses of different recurrence-risk stratification and TNM stages were contrasted,and the influencing factors to ER were analyzed by multiple-factor analysis.

Results:

The percentage of the responses obtained 3 months and 2 years after 131I therapy were(3 months/2 years)as follows54.9%/73.0%,33.3%/18.1%,11.8%/6.0%,and 0/3.4%.Of the initial IR patients,45.6% were observed to transfer into ER and 28.6% of the BIR patients are confirmed cervical recurrence by pathology.Recurrence-risk stratification and ER rate were negatively correlated(r=0.973,P=0.147);however,TNM stage and response showed no evident correlation.The size of tumor and the number of lymph node metastasis were the main influencing factors in obtaining ER(P=0.008,0.007,respectivtly).

Conclusion:

The rate of ER in non-metastasis DTC patients increased gradually after receiving 131I therapy.Approximately half of initial IR patients reached ER two years after treatment,and the patients with small diameter of tumor and less lymph node invasion tend to obtain ER.

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Idioma: Chinês Revista: Chinese Journal of Clinical Oncology Ano de publicação: 2018 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Idioma: Chinês Revista: Chinese Journal of Clinical Oncology Ano de publicação: 2018 Tipo de documento: Artigo